The RMAT designation is intended to expedite the development and evaluation of regenerative medicine therapies.

NouvNeu004: Recently received I-III all-stage IND approval from the NMPA, making it the world's first cell therapy product for Multiple System Atrophy (MSA) and iRegene's third self-developed product ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

Explore Duopa, an advanced Parkinson's disease treatment that uses carbidopa-levodopa gel infusion for steady dopamine levels, reducing motor fluctuations effectively.

What’s exciting about this current moment, says Jonathan Brotchie, founder and CEO of Toronto-based Atuka, which specializes ...

A new initiative is set to explore the potential of repurposing existing medications to combat the symptoms of both Alzheimer’s and Parkinson’s diseases, aiming to accelerate the discovery of novel ...

Lysosomes are the recycling centers of human cells. Larger molecules are broken down inside the membrane-enclosed vesicles. Malfunctions can lead to neurodegenerative diseases such as Parkinson's.

Northwestern Medicine scientists have discovered that targeting neuronal signaling controlling aberrant learning in the striatum may improve the efficacy of a first-line therapy for Parkinson's ...

In the late 1960s, scientists discovered a miracle drug for Parkinson’s disease — a simple, inexpensive dopamine-replacement pill called levodopa. It transformed the lives of millions of people.

The metabolite of a drug that is helping patients battle multiple sclerosis appears to significantly slow the onset of Parkinson's disease, researchers say. The oral drug, dimethylfumarate, or DMF, ...